280 related articles for article (PubMed ID: 29654751)
21. Cost-effectiveness of self-injected DMPA-SC compared with health-worker-injected DMPA-IM in Senegal.
Mvundura M; Di Giorgio L; Morozoff C; Cover J; Ndour M; Drake JK
Contracept X; 2019; 1():100012. PubMed ID: 32494776
[TBL] [Abstract][Full Text] [Related]
22. Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.
Burke HM; Mueller MP; Packer C; Perry B; Bufumbo L; Mbengue D; Daff BM; Mbonye A
Contraception; 2014 May; 89(5):368-73. PubMed ID: 24576792
[TBL] [Abstract][Full Text] [Related]
23. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
25. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
[TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
Beasley A; White KO; Cremers S; Westhoff C
Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
[TBL] [Abstract][Full Text] [Related]
27. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
[TBL] [Abstract][Full Text] [Related]
28. Injectable contraception: emerging evidence on subcutaneous self-administration.
Lerma K; Goldthwaite LM
Curr Opin Obstet Gynecol; 2019 Dec; 31(6):464-470. PubMed ID: 31567445
[TBL] [Abstract][Full Text] [Related]
29. Acceptability of the distribution of DMPA-SC by community health workers among acceptors in the rural province of Lualaba in the Democratic Republic of the Congo: a pilot study.
Mwembo A; Emel R; Koba T; Sankoko JB; Ngay A; Gay R; Bertrand JT
Contraception; 2018 Nov; 98(5):454-459. PubMed ID: 30118683
[TBL] [Abstract][Full Text] [Related]
30. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
31. The effect of job aids on knowledge retention among Patent and Proprietary Medicine Vendors trained to administer injectable contraceptives: longitudinal results from implementation science in Nigeria.
Chace Dwyer S; Jain A; Ishaku SM; Okunade FT; Uzomba C; Adebayo A; Tobey E
BMC Public Health; 2019 Oct; 19(1):1362. PubMed ID: 31651273
[TBL] [Abstract][Full Text] [Related]
32. An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.
Bertrand JT; Bidashimwa D; Makani PB; Hernandez JH; Akilimali P; Binanga A
Contraception; 2018 Nov; 98(5):411-417. PubMed ID: 30120925
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two strategies for the administration of injectable depot medroxyprogesterone acetate: among women who returned to a family planning clinic at three- or six-month intervals.
Ferreira JM; Bottura BF; Gonçalves MP; Monteiro I; Bahamondes L
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):408-11. PubMed ID: 27530899
[TBL] [Abstract][Full Text] [Related]
34. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
Potter LS; Dalberth BT; Cañamar R; Betz M
Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
[TBL] [Abstract][Full Text] [Related]
35. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
Prabhakaran S; Sweet A
Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
[TBL] [Abstract][Full Text] [Related]
36. Strategies to improve adherence and acceptability of hormonal methods of contraception.
Halpern V; Lopez LM; Grimes DA; Stockton LL; Gallo MF
Cochrane Database Syst Rev; 2013 Oct; (10):CD004317. PubMed ID: 24163097
[TBL] [Abstract][Full Text] [Related]
37. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
Katz M; Newmark RL; Aronstam A; O'Grady N; Strome S; Rafie S; Karlin J
Contraception; 2020 Dec; 102(6):392-395. PubMed ID: 32931811
[TBL] [Abstract][Full Text] [Related]
38. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV; Gaffield ME
Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
[TBL] [Abstract][Full Text] [Related]
39. Adolescent and covert family planning users' experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate.
Burke HM; Packer C; Wando L; Wandiembe SP; Muwereza N; Pradhan S; Zingani A; Ngwira B
Reprod Health; 2020 Aug; 17(1):117. PubMed ID: 32746860
[TBL] [Abstract][Full Text] [Related]
40. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
Williams RL; Hensel DJ; Fortenberry JD
Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
